Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | BMC Musculoskeletal Disorders

Fig. 3

From: In vitro chondrogenic potency of surplus chondrocytes from autologous transplantation procedures does not predict short-term clinical outcomes

Fig. 3

Comparison of donor-matched chondrogenic potential with clinical outcomes. VAS score (a), KOOS total (b) and Lysholm score (c) were plotted against chondrogenic Group A and Group B at the preoperative stage, one-year and two-year follow-up after ACI. d Patient distribution using Lysholm score (cut-off < 65) at two-year follow-up demonstrated clinical success and failure groups and their no significant association (r = −.308, p = 0.284) with in vitro chondrogenic potentials. Significance level, p (*) < 0.05

Back to article page